Home/Atrium Therapeutics/Kath Gallagher
KG

Kath Gallagher

Chief Executive Officer (CEO)

Atrium Therapeutics

Atrium Therapeutics Pipeline

DrugIndicationPhase
ATR 1072PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) SyndromePre-clinical
ATR 1086PLN (Phospholamban) CardiomyopathyPre-clinical
Undisclosed Research Target 1Rare CardiomyopathyResearch
Undisclosed Research Target 2Rare CardiomyopathyResearch